XML 18 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Product revenues $ 591 $ 1,333
Cost of product revenues (excluding below amortization of intangible assets) 410 468
Amortization of intangible assets 306 99
Gross (loss) profit (125) 766
Development revenues:    
Government contracts and other 1,018 1,585
Total development revenues 1,018 1,585
Operating expenses:    
Research and development 3,289 4,127
Sales and marketing 939 1,035
General and administrative 2,108 2,286
Total operating expenses 8,022 7,448
Operating loss (7,129) (5,097)
Other income (expense):    
Interest income 11 2
Interest expense (591) (657)
Other income, net 165 413
Total other expense (415) (242)
Net loss $ (7,544) $ (5,339)
Basic and diluted net loss per share $ (0.33) $ (0.41)
Basic and diluted weighted average shares used in calculating net loss per share 22,736,366 13,086,376
Comprehensive loss:    
Net loss $ (7,544) $ (5,339)
Other comprehensive loss – foreign currency translation adjustments (60) (249)
Comprehensive loss (7,604) (5,588)
Azaya Therapeutics, Inc. [Member]    
Operating expenses:    
In process research and development acquired $ 1,686 $ 0